Metraipolis › archive › dc_92156cc51caa

Two Stage Designs for Phase III Clinical Trials — Europe PMC PPR:PPR195372

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR195372
DOI
10.1101/2020.07.29.20164525
License (as archived)
CC0-1.0
Archived
2026-11-07T21:44:01.997Z
SHA-256 of the archived text
8e82fd838c5e6d7b8505720cf20f629f8ab539b8cb3096fef8ef32452ea54457
Stable URL of this page
https://metraipolis.com/documento/dc_92156cc51caa

How to cite

Two Stage Designs for Phase III Clinical Trials — Europe PMC PPR:PPR195372 — Europe PMC, https://europepmc.org/article/PPR/PPR195372 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_92156cc51caa (Metraipolis archive dc_92156cc51caa, sha256 8e82fd838c5e6d7b8505720cf20f629f8ab539b8cb3096fef8ef32452ea54457)
BibTeX
@misc{dc92156cc51caa,
  title = {Two Stage Designs for Phase III Clinical Trials — Europe PMC PPR:PPR195372},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR195372},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_92156cc51caa; sha256 8e82fd838c5e6d7b8505720cf20f629f8ab539b8cb3096fef8ef32452ea54457},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR195372. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Phase III platform trials are increasingly used to evaluate a sequence of treatments for a specific disease. Traditional approaches to structure such trials tend to focus on the sequential questions rather than the performance of the entire enterprise. We consider two-stage trials where an early evaluation is used to determine whether to continue with an individual study. To evaluate performance, we use the ratio of expected wins (RW), that is, the expected number of reported efficacious treatments using a two-stage approach compared to that using standard phase III trials. We approximate the test statistics during the course of a single trial using Brownian Motion and determine the optimal stage 1 time and type I error rate to maximize RW for fixed power. At times, a surrogate or intermediate endpoint may provide a quicker read on potential efficacy than use of the primary endpoint at stage 1. We generalize our approach to the surrogate endpoint setting and show improved performance, provided a good quality and powerful surrogate is available. We apply our methods to the design of a platform trial to evaluate treatments for COVID-19 disease.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: medRxiv, 2020 (prima pubblicazione 2020-08-03).
Identificativi: DOI 10.1101/2020.07.29.20164525.
Pagina: https://europepmc.org/article/PPR/PPR195372 — https://doi.org/10.1101/2020.07.29.20164525. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T21:40:00.984Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.